Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders
Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company focused on neurodegenerative and metabolic disorders treatments, held its annual general and special meeting of shareholders on September 26, 2025. The meeting saw strong participation with 100% of Class A Multiple Voting Shares and 46.352% of Class B Subordinate Voting Shares represented.
All seven nominated directors were successfully elected with over 99.6% approval rates. Shareholders also approved the re-appointment of MNP LLP as auditor with 99.588% support and authorized the potential issuance of up to 56 additional Class A Multiple Voting Shares, receiving 90.992% approval from eligible Class B shareholders.
Quantum BioPharma (NASDAQ: QNTM), una società biofarmaceutica focalizzata sui trattamenti per malattie neurodegenerative e metaboliche, ha tenuto la propria assemblea generale annuale e speciale dei soci il 26 settembre 2025. L’assemblea ha registrato una forte partecipazione con il 100% delle azioni di Classe A a voto multiplo e il 46,352% delle azioni di Classe B a voto subordinato rappresentate.
Tutti i sette amministratori nominati sono stati eletti con tassi di approvazione superiori al 99,6%. Gli azionisti hanno anche approvato la riaffidamento di MNP LLP quale revisore contabile con il 99,588% di sostegno e hanno autorizzato la potenziale emissione di fino a 56 ulteriori azioni di Classe A a voto multiplo, ricevendo l’approvazione del 90,992% degli azionisti idonei di Classe B.
Quantum BioPharma (NASDAQ: QNTM), una empresa biofarmacéutica enfocada en tratamientos para trastornos neurodegenerativos y metabólicos, celebró su junta general anual y extraordinaria de accionistas el 26 de septiembre de 2025. La reunión registró una participación sólida con el 100% de las acciones de Clase A con voto múltiple y el 46,352% de las acciones de Clase B con voto subordinado representadas.
Los siete directores nominados fueron elegidos con éxito con más de el 99,6% de aprobación. Los accionistas también aprobaron la reelección de MNP LLP como auditor con un apoyo del 99,588% y aprobaron la posible emisión de hasta 56 acciones adicionales de Clase A con voto múltiple, recibiendo un 90,992% de aprobación por parte de accionistas elegibles de Clase B.
Quantum BioPharma (NASDAQ: QNTM)은 신경퇴행성 및 대사 장애 치료에 집중하는 바이오제약 회사로, 2025년 9월 26일 연례 일반 및 주주 특별 회의를 개최했습니다. 회의에는 다중 의결권을 가진 A클래스 주식의 100%과 종속 의결권을 가진 B클래스 주식의 46.352%가 대표되었습니다.
선출된 7명의 이사 전원이 99.6% 이상의 찬성으로 성공적으로 선출되었습니다. 주주들은 또한 감사인으로서 MNP LLP의 재임을 99.588%의 지지로 승인했으며, A클래스 다중 의결권 주식 최대 56주를 추가 발행할 수 있는 권한을 부여했고, 이는 해당 B클래스 주주들의 90.992%의 찬성을 얻었습니다.
Quantum BioPharma (NASDAQ: QNTM), une société biopharmaceutique axée sur les traitements des troubles neurodégénératifs et métaboliques, a tenu son assemblée générale annuelle et sa réunion extraordinaire des actionnaires le 26 septembre 2025. La participation a été élevée avec 100% des actions de Classe A à droit de vote multiple et 46,352% des actions de Classe B à droit de vote subordinate représentées.
Tous les sept administrateurs nommés ont été élus avec plus de 99,6% de votes favorables. Les actionnaires ont également approuvé le renouvellement de MNP LLP en tant qu’auditeur avec 52? de soutien 99,588% et ont autorisé l’émission potentielle de jusqu’à 56 actions additionnelles de Classe A à droit de vote multiple, obtenant l’approbation de 90,992% des actionnaires éligibles de Classe B.
Quantum BioPharma (NASDAQ: QNTM), ein biopharmazeutisches Unternehmen, das sich auf Behandlungen neurodegenerativer und metabolischer Erkrankungen konzentriert, hat am 26. September 2025 seine ordentliche und außerordentliche Hauptversammlung der Aktionäre abgehalten. Die Versammlung verzeichnete eine starke Beteiligung mit 100% der Aktien der Klasse A mit Mehrfachstimmrechten und 46,352% der Aktien der Klasse B mit untergeordneten Stimmrechten vertreten.
Alle sieben nominierten Direktoren wurden mit einer Zustimmungsrate von über 99,6% erfolgreich gewählt. Die Aktionäre billigten außerdem die Wiederbestellung von MNP LLP als Abschlussprüfer mit 99,588% Unterstützung und bevollmächtigten die potenzielle Emission von bis zu 56 zusätzlichen Aktien der Klasse A mit Mehrfachstimmrechten, was 90,992% Zustimmung der berechtigten Klasse-B-Aktionäre erhielt.
Quantum BioPharma (NASDAQ: QNTM)، شركة أدوية حيوية حيوية تركز على علاجات الاضطرابات العصبية-الترميمية والمتعلقة بالتمثيل الغذائي، عقدت اجتماعها العام السنوي والاجتماعي الخاص بالمساهمين في 26 سبتمبر 2025. شهد الاجتماع مشاركة قوية مع تمثُّل 100% من أسهم الفئة A ذات التصويت المتعدد و< b>46.352% من أسهم الفئة B ذات التصويت التبعي.
تم انتخاب جميع المدراء السبعة المرشحين بنجاح بأكثر من 99.6% من الأصوات. كما وافق المساهمون على إعادة تعيين MNP LLP كمدقق حسابات بـ دعم 99.588% ومنحوا تفويضًا بإصدار حتى 56 سهمًا إضافيًا من فئة A ذات التصويت المتعدد، مع حصولهم على 89.992%؟ من التصويت من مساهمي الفئة B المؤهلين.
Quantum BioPharma (NASDAQ: QNTM)，一家专注于神经退行性疾病和代谢疾病治疗的生物制药公司，于2025年9月26日举行了年度股东大会及特别股东大会。会议参与度很高，代表了100%的A类多重投票权股和46.352%的B类从属投票股。
七位提名的董事均已成功当选，获得<超过99.6%的赞成票。股东还以<99.588%的支持通过了再次任命MNP LLP为审计师，并授权可能发行最多56股额外的A类多重投票权股票，获得了<来自符合条件的B类股东的90.992%的批准。
- High shareholder participation and strong support for board nominees with >99.6% approval
- Overwhelming support (99.588%) for auditor reappointment
- Strong backing (90.992%) for the authorization of additional Class A Multiple Voting Shares issuance
- Potential dilution risk from authorization to issue up to 56 additional Class A Multiple Voting Shares
- 9.008% opposition to the Class A Multiple Voting Shares Issuance Resolution
TORONTO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, is pleased to announce today the results of its annual general and special meeting of shareholders, held on Friday, September 26, 2025 in person at 801-1 Adelaide Street East, Toronto, ON M5C 2V9 (“AGSM”).
There were shareholders represented in person or by proxy at the AGSM holding 12 class A multiple voting shares (the “Class A Multiple Voting Shares”) and 1,769,228 class B subordinate voting shares (the “Class B Subordinate Voting Shares”), representing
Each nominee listed in the Company’s management information circular dated August 14, 2025, was elected as a director of the Company. Each director will serve until the next annual meeting of shareholders or until his or her successor is duly elected or appointed. The results of which were as follows:
| Nominee | Votes For | % Votes For | |
| Anthony Durkacz | 4,200,352 | ||
| Zeeshan Saeed | 4,194,933 | ||
| Dr. Lakshmi P. Kotra | 4,198,379 | ||
| Adnan Bashir | 4,192,338 | ||
| Terry Lynch | 4,197,772 | ||
| Michael (Zappy) Zapolin | 4,197,828 | ||
| Dr. Eric Hoskins | 4,198,027 | 99.825% | |
In addition, at the AGSM, the shareholders also: (i) re-appointed MNP LLP as the Company’s auditor (the “Auditor”) and authorized the directors to fix the Auditor’s remuneration; and (ii) the holders of Class B Subordinate Voting Shares, exclusive of Class B Subordinate Voting Shares held by holders of Class A Multiple Voting Shares, passed an ordinary resolution authorizing the Board to approve, in its sole discretion, the issuance of up to an additional 56 Class A Multiple Voting Shares until the Company’s next annual meeting, as further described in the Circular (the “Class A Multiple Voting Shares Issuance Resolution”).
| Resolution | Votes For: | Votes Withheld: | Votes Against: | ||||||
| Number | Percentage | Number | Percentage | Number | Percentage | ||||
| Re-appointment of Auditor | 5,068,184 | 99.588 | % | 20,963 | 0.412 | % | 0 | 0.000 | % |
| Approval of Class A Multiple Voting Shares Issuance Resolution | 808,461 | 90.992 | % | 0 | 0.000 | % | 80,037 | 9.008 | % |
For more information on these matters and capitalized terms used in this press release but not defined herein, please refer to the Company’s management information circular dated August 14, 2025, on SEDAR+ at www.sedarplus.ca. Details of the Company's report of voting results are available under the Company's SEDAR+ profile.
About Quantum BioPharma Ltd.
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), now Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of
For more information visit www.quantumbiopharma.com
Forward Looking Information
This press release contains “forward-looking statements” within the meaning of applicable securities laws, including statements regarding the Board’s discretion to approve the issuance of up to 56 additional Class A Multiple Voting Shares until the Company’s next annual meeting and the Company’s business goals. Forward-looking statements are based on assumptions that the Company believes are reasonable as at the date hereof, including assumptions regarding market conditions, corporate approvals, compliance with applicable stock exchange and corporate law requirements, and the continuity of the Company’s strategy. Forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied, including risks related to regulatory and stock exchange approvals, timing and implementation of corporate actions, dilution, market volatility, financing availability, and the factors discussed under “Risk Factors” in the Company’s filings on SEDAR+ and EDGAR. Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements.
Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. The Company cautions that although it believes the expectations and material factors and assumptions reflected in these forward-looking statements are reasonable as of the date hereof, there can be no assurance that these expectations, factors and assumptions will prove to be correct and these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements, of which assumptions include: the Company will satisfy all applicable listing and regulatory requirements of the Canadian Securities Exchange and Nasdaq-CM on an ongoing basis; the ability of the Company to receive regulatory approval for the resolutions that were approved at the AGSM; the fact that the drug development efforts of the Company and Lucid are at a very early stage; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company and Lucid may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company and Lucid; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the potential inability to obtain or maintain regulatory approval of the drug product candidates of the Company and Lucid; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company and Lucid; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the potential inability to obtain adequate financing; the potential inability to obtain or maintain intellectual property protection for the drug product candidates of the Company and Lucid; the Company's inability to realize upon the benefits, claims, and timelines with respect to unbuzzd™; the Company's inability to realize upon the stated benefit from the partnerships of Unbuzzd Wellness Inc.; the Company's inability to carryout its business and goals, including the continued research and development of Lucid-MS, unbuzzd™, novel formulations for alcohol misuse disorders, and treatments for use in the healthcare sector; the Board will exercise its discretion to approve the issuance of up to 56 additional Class A Multiple Voting Shares prior to the Company’s next annual meeting; and the Company's inability to maintain its strategic investment portfolio. Accordingly, readers should not place undue reliance on the forward-looking statements contained in this press release, which speak only as of the date of this press release.
These forward-looking statements are not guarantees of future performance and are subject to a number of known and unknown risks and uncertainties including, but not limited to: the timing and ability to satisfy all applicable listing and regulatory requirements of the Canadian Securities Exchange and Nasdaq-CM; reliance on management and key personnel; the fact that the drug development efforts of the Company and Lucid are at a very early stage; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company and Lucid may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company and Lucid; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the potential inability to obtain or maintain regulatory approval of the drug product candidates of the Company and Lucid; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company and Lucid; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the potential inability to obtain adequate financing; the potential inability to obtain or maintain intellectual property protection for the drug product candidates of the Company and Lucid; the Company's inability to realize upon the benefits, claims, and timelines with respect to unbuzzd™; the Company's inability to realize upon the stated benefit from the partnerships of Unbuzzd Wellness Inc.; the Company's inability to carryout its business and goals, including the continued research and development of Lucid-MS, unbuzzd™, novel formulations for alcohol misuse disorders, and treatments for use in the healthcare sector; the Board’s discretion and ability to approve the issuance of up to 56 additional Class A Multiple Voting Shares prior to the Company’s next annual meeting; and the Company's inability to maintain its strategic investment portfolio. Accordingly, readers should not place undue reliance on the forward-looking statements contained in this press release, which speak only as of the date of this press release.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
The Company makes no medical, treatment or health benefit claims about unbuzzd™. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated any claims regarding unbuzzd™. The efficacy of such products have not been confirmed by approved research. Rigorous scientific research and clinical trials are needed. No clinical trials for the use of the Company's proposed products have been conducted. Any references to quality, consistency, efficacy and safety of potential products do not imply that the Company verified such in clinical trials or that the Company will complete such trials.
Neither the Canadian Securities Exchange nor its regulation services provider accept responsibility for the adequacy or accuracy of this release.
Contacts
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Investor Relations
Investor Relations: IR@QuantumBioPharma.com
General inquiries: info@QuantumBioPharma.com
FAQ
What were the key results of Quantum BioPharma's (QNTM) 2025 annual shareholder meeting?
What was the shareholder participation rate at QNTM's 2025 annual meeting?
Who are the directors elected to Quantum BioPharma's board in 2025?
What was the voting result for QNTM's Class A Multiple Voting Shares issuance resolution?
